Gabapentin Market Size To Rise USD 4.68 Billion By 2032

Published Date : 28 Nov 2023

The gabapentin market size is estimated at USD 2.6 billion in 2022 and is expected to reach USD 4.68 billion by 2032, growing at a CAGR of 6.10% during the forecast period.

Gabapentin Market Size and Growth Rate 2023 To 2032

Market Overview

Gabapentin is a medication that is commonly used to treat certain types of seizures and to relieve nerve pain. It belongs to a class of drugs known as anticonvulsants or antiepileptic drugs. The exact way in which gabapentin works is not fully understood, but it is believed to affect the way nerves in the brain send messages to each other. In addition to its anticonvulsant properties, gabapentin is also prescribed to manage neuropathic pain, which is pain caused by damage or irritation to the nerves. Conditions for which gabapentin may be prescribed include postherpetic neuralgia, diabetic neuropathy and other forms of chronic pain.

Growth Factors

The gabapentin market is driven by various factors including increasing incidence of seizures, growing older population, rising government initiatives, R&D investment, growing use in neuropathic pain treatment and others. Furthermore, the growing product launches is another important factor that propel the market growth over the forecast period. For instance, in September 2023, renowned multinational pharmaceutical corporation Lotus Pharmaceutical teamed up with top B2B pharmaceutical firm Adalvo to introduce Gabapentin ER 300 / 600 mg in South Korea. 

As per Epilepsy Foundation, seizures and epilepsy may strike anyone at any age. Older adults and small children are more likely to suffer from epilepsy and seizures. One in every 100 Americans has been diagnosed with epilepsy or has experienced one spontaneous seizure. A person's lifetime risk of developing epilepsy is also 1 in 26. Certain people could be more vulnerable than others.

According to the Institute for Health Metrics and Evaluation, the prevalence of diabetes is 6.1% worldwide, placing it among the top 10 causes of death and disability. North Africa and the Middle East have the highest rate at the super region level, which is 9.3%. By 2050, it is predicted that this rate would rise to 16.8%. It is anticipated that the rate in Latin America and the Caribbean will rise to 11.3%.

Regional Insights

North America is expected to dominate the gabapentin market over the anticipated timeframe. The market growth in the region is attributed to the presence of major pharmaceutical companies such as Pfizer, Mylan NV, Amneal Pharmaceuticals and others. Moreover, the demand for gabapentin in North America is likely to be influenced by the prevalence of conditions for which gabapentin is prescribed, such as neuropathic pain and epilepsy. An ageing population and a high incidence of diabetes are factors that may contribute to neuropathic pain. For instance, as per the data from the diabetes research institute, 11.3% of Americans, or 37.3 million individuals, suffer from diabetes. 28.7 million persons were projected to have been diagnosed with diabetes. 8.6 million people worldwide suffer from diabetes but are not yet diagnosed.

In the region, the US held a prominent market share in 2022 and is expected to continue its dominance over the forecast period. The growth in the US is attributed to the prevalence of various movement disorders, including Parkinson's. For instance, according to the result of a new study by the American Parkinson Disease Association in 2023, Parkinson's disease (PD) incidence, or the number of new cases identified per year, is thought to be 50% greater than previously estimated. Approximately 90,000 new instances of PD are identified in the US each year, according to a new study, compared to previous estimates of 60,000 new cases.

Gabapentin Market Scope

Report Coverage Details
Market Size in 2023 USD 2.75 Billion
Market Size by 2032 USD 4.68 Billion
Growth Rate from 2023 to 2032 CAGR of 6.10%
Largest Market North America
Base Year 2022
Forecast Period 2023 To 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Dynamics


Growing ageing population

The ageing population is increasingly vulnerable to neuropathic pain and other medical conditions. The need for medication, such as gabapentin, to treat age-related health concerns is growing as the world's population ages. For instance, according to the Australian Bureau of Statistics, due to chronic low fertility and rising life expectancy, Australia's population is expected to age. The number of people 65 and older is expected to nearly double from 3.8 million in 2017 to between 6.4 million and 6.7 million in 2042. Therefore, the aforementioned stats drive the market expansion over the projected timeframe.

Increasing prevalence of neuropathic pain

Gabapentin is commonly prescribed for neuropathic pain conditions, and as awareness of these conditions grows, the demand for medications like gabapentin might increase. For instance, according to the international association for the study of pain, the prevalence of NeuP in the general population is between 7% and 10%, and in individuals with diabetes, it rises to between 20% and 30%. Previous research has also shown that older adults, women, and residents of high-socioeconomic deprivation regions had a higher prevalence of NeuP, as does the general population with chronic pain. Therefore, the increasing prevalence of neuropathic pain drives the demand for gabapentin industry during the projected period.


Side effects and tolerance issues

Gabapentin, like any medication, may cause side effects, and individuals may develop tolerance over time, requiring dose adjustments. Concerns related to side effects or the need for dose increases might impact patient compliance and overall market demand. For instance, the adverse effects of gabapentin include respiratory failure, weaker muscles, and memory loss.  

Alternative treatment option

The availability of alternative treatment medications or therapies for conditions such as neuropathic pain and epilepsy could impact the market for gabapentin. The development of new and more effective treatments may shift prescribing patterns. For instance, the anti-epileptic drugs include sodium valproate, carbamazepine, lamotrigine, levetiracetam and topiramate. Thus, the availability of a variety of drugs might be a major restraining factor for the market development.


Increasing usage as a pain management drug

Gabapentin's use as a pain reliever, especially for neuropathic pain, is one of the main things driving up demand for the drug. The growing incidence of chronic pain disorders that are challenging to treat with traditional opioids, such as diabetic neuropathy, shingles, and spinal cord injuries, is propelling the market. While gabapentin was initially created and administered to treat epilepsy and seizures, the number of doctors who are now using the drug "off-label" for both acute and chronic pain has increased fivefold in the last few years. While some prescribe it in addition to opioids, others prescribe it instead of them.        

Increasing awareness and education initiatives  

There is an important opportunity for market expansion through campaigns to raise knowledge of the advantages of gabapentin, how best to use it, and any possible negative effects. Its acceptability and adoption can be improved by educating patients, caregivers, and healthcare professionals on the safe and effective use of gabapentin, as well as its effectiveness in addressing a range of diseases. In addition to increasing market share, this instructional strategy may promote responsible usage more quickly, which is essential for assuring favorable results and reducing potential hazards.

Recent Developments

  • In July 2023, to evaluate the effectiveness and safety of OK-101 in treating patients with neuropathic corneal pain (NCP), OKYO Pharma Ltd. announced a new collaboration with Tufts Medical Center to carry out an open-label clinical investigation.
  • In May 2023, to position the company for a new age of growth, Teva Pharmaceutical Industries Ltd. unveiled a new strategic framework with four primary pillars. With the help of AUSTEDO®, AJOVY®, UZEDYTM, and biosimilars, the company hopes to strengthen its robust commercial portfolio. It also hopes to reinforce its innovation pipeline, maintain its position as a leader in generics, and narrow its business focus. It is anticipated that these four pillars would increase value and have a bigger effect on patients.

Gabapentin Market Players

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Novartis AG
  • Amneal Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Sandoz International GmbH

Segments Covered in the Report

By Dosage

  • Tablet
  • Capsule
  • Oral Solution

By Type

  • Generic
  • Branded

By Application

  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 650 460 3308